Export directly to RefWorks

TY  - BOOK
ID  - 14220934
TI  - Biopatent law : European vs. US patent law
AU  - Storz, Ulrich.
AU  - Storz, Ulrich
AU  - Quodbach, Martin
AU  - Marty, Scott D.
AU  - Constantine, Derek E.
AU  - Parker, Matthew
PY  - 2014
SN  - 3642412920 3642412939
PB  - New York : Springer,
DB  - UniCat
KW  - Biotechnology
KW  - Law and legislation
KW  - Medicine.
KW  - Molecular biology.
KW  - Biochemistry.
KW  - International law.
KW  - Intellectual property
KW  - Biomedicine.
KW  - Molecular Medicine.
KW  - International IT and Media Law, Intellectual Property Law.
KW  - Biochemistry, general.
KW  - Law and legislation.
KW  - Chemical engineering
KW  - Genetic engineering
KW  - Mass media
KW  - IT Law, Media Law, Intellectual Property.
KW  - Biological chemistry
KW  - Chemical composition of organisms
KW  - Organisms
KW  - Physiological chemistry
KW  - Biology
KW  - Chemistry
KW  - Medical sciences
KW  - Clinical sciences
KW  - Medical profession
KW  - Human biology
KW  - Life sciences
KW  - Pathology
KW  - Physicians
KW  - Composition
KW  - Mass media.
KW  - Law.
KW  - Acts, Legislative
KW  - Enactments, Legislative
KW  - Laws (Statutes)
KW  - Legislative acts
KW  - Legislative enactments
KW  - Jurisprudence
KW  - Legislation
KW  - Mass communication
KW  - Media, Mass
KW  - Media, The
KW  - Communication
KW  - Molecular biochemistry
KW  - Molecular biophysics
KW  - Biochemistry
KW  - Biophysics
KW  - Biomolecules
KW  - Systems biology
KW  - Medicine
KW  - Information technology
KW  - Biomedical Research.
KW  - Research.
KW  - Technology and law
KW  - Biological research
KW  - Biomedical research
KW  - Health Workforce
KW  - Patents.
UR  - https://www.unicat.be/uniCat?func=search&query=sysid:14220934
AB  - SpringerBriefs in Biotech Patents presents timely reports on intellectual properties (IP) issues and patent aspects in the field of biotechnology. This volume focus on particular aspects of the US patent law, which can have tremendous differences compared to the European law. This includes questions of biopatent prosecution, novelty, inventive step, written disclosure and sufficiency of enablement as well as questions of law enforcement of biotech patents.
ER  -